Uipath Inc (PATH) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Sep 9, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2027, filed Sep 8, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the PATH SEC filings page.
Uipath Inc (PATH) reported $1.7B in revenue over the twelve months to Jul 31, 2026, up 15.0% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
UiPath’s dominant shift is from scale-funded losses to cash-generative profitability through operating-cost absorption
Earnings quality improved materially in FY2026: operating cash flow reached$371M versus net income of$282M , while free cash flow was$352M . However, the unusually large negative income-tax expense of-$182M helped lift net income well above operating income of$57M , so cash generation provides the cleaner measure of underlying performance.
Margin expansion came mainly below gross profit, not from a dramatic change in product economics: gross margin stayed within roughly
Capital allocation is consuming part of the internally generated cash: FY2026 share repurchases totaled
Financial Health Signals
Scored against operating companies for FY2026. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Uipath Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Uipath Inc has an operating margin of 3.5%, meaning the company retains $4 of operating profit per $100 of revenue. This below-average margin results in a low score of 29/100, suggesting thin profitability after operating expenses. This is up from -11.4% the prior year.
Uipath Inc's revenue grew 12.7% year-over-year to $1.6B, a solid pace of expansion. This earns a growth score of 67/100.
Uipath Inc has a moderate D/E ratio of 0.53. This balance of debt and equity financing earns a leverage score of 60/100.
With a current ratio of 2.48, Uipath Inc holds $2.48 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.
Uipath Inc converts 21.9% of revenue into free cash flow ($352.2M). This strong cash generation earns a score of 88/100.
Uipath Inc's ROE of 13.6% shows moderate profitability relative to equity, earning a score of 30/100. This is up from -4.0% the prior year.
Uipath Inc scores 4.29, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($7.3B) relative to total liabilities ($1.1B). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Uipath Inc passes 6 of 7 computable financial strength tests (2 of the nine could not be computed from available data). All 4 profitability signals pass (positive income, cash flow, and earnings quality), no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.
For every $1 of reported earnings, Uipath Inc generates $1.31 in operating cash flow ($371.2M OCF vs $282.3M net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
Key Financial Metrics
Earnings & Revenue
Uipath Inc generated $410.3M in revenue in Q2 2027. This represents an increase of 13.4% from the same quarter a year earlier. Against the prior quarter it is down 1.9%.
Uipath Inc's EBITDA was $39.9M in Q2 2027, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 339.2% from the same quarter a year earlier. Against the prior quarter it is up 12.4%.
Uipath Inc reported $36.1M in net income in Q2 2027. This represents an increase of 2178.3% from the same quarter a year earlier. Against the prior quarter it is up 60.2%.
Uipath Inc earned $0.07 per diluted share (EPS) in Q2 2027. Against the prior quarter it is up 75.0%.
Cash & Balance Sheet
Uipath Inc generated $29.3M in free cash flow in Q2 2027, representing cash available after capex. This represents a decrease of 29.5% from the same quarter a year earlier. Against the prior quarter it is down 77.3%.
Uipath Inc held $607.4M in cash as of Q2 2027; long-term debt is not reported for that period.
Not reported for Q2 2027.
Margins & Returns
Uipath Inc's gross margin was 80.4% in Q2 2027, indicating the percentage of revenue retained after direct costs. This is down 1.8 percentage points from the same quarter a year earlier. Against the prior quarter it is down 1.3 percentage points.
Uipath Inc's operating margin was 7.7% in Q2 2027, reflecting core business profitability. This is up 13.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.0 percentage points.
Uipath Inc's net profit margin was 8.8% in Q2 2027, showing the share of revenue converted to profit. This is up 8.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.4 percentage points.
Uipath Inc's ROE was 1.8% in Q2 2027, measuring profit generated per dollar of shareholder equity. This is up 1.7 percentage points from the same quarter a year earlier. Against the prior quarter it is up 0.7 percentage points.
Capital Allocation
Uipath Inc invested $83.4M in research and development in Q2 2027. This represents a decrease of 15.2% from the same quarter a year earlier. Against the prior quarter it is down 10.2%.
Uipath Inc spent $24.8M on share buybacks in Q2 2027, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 75.6% from the same quarter a year earlier. Against the prior quarter it is down 89.8%.
Uipath Inc invested $1.4M in capex in Q2 2027, funding long-term assets and infrastructure. Against the prior quarter it is down 48.2%.
PATH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Revenue | $410.3M+13.4% | $418.4M+17.3% | $481.1M+13.6% | $411.1M+15.9% | $361.7M+14.4% | $356.6M+6.4% | $423.6M+4.5% | $354.7M+8.8% |
| Cost of Revenue | $80.6M+25.2% | $76.9M+20.5% | $73.9M+14.6% | $68.8M+7.9% | $64.4M+1.7% | $63.9M+15.4% | $64.5M+21.0% | $63.8M+27.7% |
| Gross Profit | $329.7M+10.9% | $341.5M+16.6% | $407.2M+13.4% | $342.3M+17.7% | $297.3M+17.6% | $292.8M+4.6% | $359.1M+2.0% | $290.9M+5.4% |
| R&D Expenses | $83.4M-15.2% | $92.9M-2.0% | $95.2M-4.5% | $96.9M-0.1% | $98.3M-0.1% | $94.8M+10.8% | $99.7M+16.4% | $97.0M+14.7% |
| SG&A Expenses | $50.1M-5.3% | $52.7M-3.6% | $53.5M+9.3% | $53.2M+6.2% | $52.9M-16.7% | $54.7M-13.9% | $49.0M-17.6% | $50.1M-10.6% |
| Operating Income | $31.6M+256.6% | $28.0M+270.5% | $80.3M+138.9% | $13.1M+130.1% | -$20.2M+80.5% | -$16.4M+66.8% | $33.6M+122.6% | -$43.4M+22.3% |
| EBITDA | $39.9M+339.2% | $35.5M+369.7% | $86.7M+127.9% | $16.9M+142.6% | -$16.7M+83.2% | -$13.2M+70.5% | $38.0M+70.8% | -$39.6M+22.5% |
| Income Tax | $16.8M+861.9% | $18.4M+552.4% | -$12.0M-524.9% | -$174.2M-1073.9% | $1.7M-54.5% | $2.8M-25.2% | $2.8M+5.6% | -$14.8M-478.1% |
| Net Income | $36.1M+2178.3% | $22.5M+199.9% | $104.5M+101.7% | $198.8M+1966.2% | $1.6M+101.8% | -$22.6M+21.5% | $51.8M+52.7% | -$10.7M+66.2% |
| EPS (Basic) | $0.07 | $0.04+200.0% | $0.19+111.1% | $0.37+1950.0% | $0.00+100.0% | -$0.04+20.0% | $0.09+50.0% | -$0.02+66.7% |
| EPS (Diluted) | $0.07 | $0.04+200.0% | $0.19+111.1% | $0.37+1950.0% | $0.00+100.0% | -$0.04+20.0% | $0.09+50.0% | -$0.02+66.7% |
| Diluted Shares (Avg) | 523M-3.7% | 528M-3.8% | N/A | 539M-2.2% | 543M-4.4% | 548M-3.8% | N/A | 551M-2.8% |
Not reported in any period shown, so not listed: Interest Expense.
PATH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $2.9B+12.2% | $2.9B+9.8% | $3.2B+11.0% | $2.9B+8.7% | $2.6B-4.0% | $2.6B-7.0% | $2.9B-3.0% | $2.7B-4.4% |
| Current Assets | $1.9B-5.1% | $1.9B-9.1% | $2.2B-4.0% | $2.1B-3.8% | $2.0B-10.7% | $2.1B-14.6% | $2.3B-9.4% | $2.2B-10.4% |
| Cash & Equivalents | $607.4M-3.4% | $632.2M-9.8% | $871.2M-0.9% | $743.7M-3.9% | $628.6M-33.1% | $700.6M-38.9% | $879.2M-17.2% | $773.6M-22.9% |
| Short-Term Investments | $676.6M-17.4% | $675.0M-21.0% | $601.3M-19.9% | $654.5M-17.7% | $818.9M+1.8% | $854.4M+8.3% | $750.3M-8.3% | $795.4M-2.3% |
| Accounts Receivable | $307.1M+13.8% | $300.0M+12.5% | $488.3M+8.2% | $366.8M+9.1% | $269.8M+0.8% | $266.6M-1.5% | $451.1M+3.4% | $336.1M-9.9% |
| Long-Term Investments | $121.0M+61.1% | $108.5M+197.5% | $217.0M+130.6% | $121.6M+253.5% | $75.2M | $36.5M+3690.7% | $94.1M | $34.4M |
| Goodwill | $179.5M+48.6% | $185.7M+53.0% | $125.3M+43.5% | $120.6M+34.2% | $120.8M+34.9% | $121.4M+37.3% | $87.3M-1.9% | $89.9M+2.9% |
| Total Liabilities | $958.8M+3.5% | $1.0B+5.9% | $1.1B+7.6% | $971.4M+4.3% | $926.6M+6.8% | $946.0M+15.6% | $1.0B+8.6% | $931.4M+12.8% |
| Current Liabilities | $807.3M+9.3% | $831.7M+16.2% | $905.4M+13.3% | $788.7M+13.4% | $738.4M+16.7% | $715.9M+19.8% | $798.9M+12.3% | $695.5M+10.8% |
| Non-Current Liabilities | $151.6M-19.5% | $170.1M-26.1% | $191.2M-13.3% | $182.7M-22.6% | $188.2M-20.0% | $230.1M+4.4% | $220.6M-2.8% | $236.0M+19.1% |
| Total Equity | $1.9B+17.0% | $1.9B+12.0% | $2.1B+12.8% | $1.9B+11.1% | $1.7B-9.2% | $1.7B-16.2% | $1.8B-8.4% | $1.7B-11.7% |
| Retained Earnings | -$1.6B+18.0% | -$1.7B+16.3% | -$1.7B+14.2% | -$1.8B+11.3% | -$2.0B+1.0% | -$2.0B-3.5% | -$2.0B-3.8% | -$2.0B-4.7% |
Not reported in any period shown, so not listed: Inventory, Long-Term Debt.
PATH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $30.7M-26.2% | $131.9M+10.9% | $182.3M+24.8% | $28.3M+0.7% | $41.6M-10.3% | $119.0M+19.0% | $146.1M+0.3% | $28.1M-32.9% |
| Depreciation & Amortization | $8.3M+137.1% | $7.5M+130.8% | $5.0M+54.7% | $3.8M0.0% | $3.5M-14.6% | $3.3M-33.6% | $3.2M-46.8% | $3.8M-20.8% |
| Stock-Based Compensation | $45.0M-42.4% | $53.3M-30.2% | N/A | $71.5M-18.3% | $78.0M-17.3% | $76.4M-13.9% | N/A | $87.5M-8.8% |
| Capital Expenditures | $1.4M | $2.7M-79.1% | $3.1M-58.7% | $3.2M-35.1% | $0-100.0% | $12.8M+936.5% | $7.4M+95.3% | $4.9M+614.8% |
| Free Cash Flow | $29.3M-29.5% | $129.2M+21.7% | $179.3M+29.3% | $25.1M+8.2% | $41.6M-7.5% | $106.2M+7.5% | $138.7M-2.2% | $23.2M-43.7% |
| Investing Cash Flow | -$15.7M-2300.6% | -$112.8M-41.2% | -$42.7M-155.5% | $100.8M+539.7% | -$655K+98.4% | -$79.9M-323.5% | -$16.7M-93.3% | -$22.9M+62.0% |
| Financing Cash Flow | -$34.9M+68.7% | -$252.2M-7.2% | -$14.4M+15.2% | -$11.2M+93.5% | -$111.6M+48.1% | -$235.2M-414.3% | -$17.0M+79.3% | -$172.6M-149.7% |
| Share Buybacks | $24.8M-75.6% | $243.8M+7.2% | $0-100.0% | $0-100.0% | $101.6M-48.4% | $227.5M+934.0% | $9.3M-81.3% | $162.7M+208.9% |
Not reported in any period shown, so not listed: Dividends Paid.
PATH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2710-Q | Q1'2710-Q | Q4'2610-Q | Q3'2610-Q | Q2'2610-Q | Q1'2610-Q | Q4'2510-K | Q3'2510-Q |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 80.4%-1.8pp | 81.6%-0.5pp | 84.6%-0.1pp | 83.3%+1.2pp | 82.2%+2.2pp | 82.1%-1.4pp | 84.8%-2.1pp | 82.0%-2.7pp |
| Operating Margin | 7.7%+13.3pp | 6.7%+11.3pp | 16.7%+8.8pp | 3.2%+15.4pp | -5.6%+27.1pp | -4.6%+10.2pp | 7.9%+4.2pp | -12.2%+4.9pp |
| Net Margin | 8.8%+8.4pp | 5.4%+11.7pp | 21.7%+9.5pp | 48.4%+51.4pp | 0.4%+27.7pp | -6.3%+2.3pp | 12.2%+3.9pp | -3.0%+6.7pp |
| Return on Equity | 1.8%+1.7pp | 1.2%+2.5pp | 5.0%+2.2pp | 10.3%+10.9pp | 0.1%+4.8pp | -1.3%+0.1pp | 2.8%+1.1pp | -0.6%+1.0pp |
| Return on Assets | 1.2%+1.2pp | 0.8%+1.6pp | 3.3%+1.5pp | 6.9%+7.3pp | 0.1%+3.3pp | -0.9%+0.2pp | 1.8%+0.7pp | -0.4%+0.7pp |
| Current Ratio | 2.39-0.4x | 2.31-0.6x | 2.48-0.4x | 2.65-0.5x | 2.75-0.8x | 2.95-1.2x | 2.93-0.7x | 3.13-0.7x |
| Debt-to-Equity | 0.49-0.1x | 0.530.0x | 0.530.0x | 0.500.0x | 0.56+0.1x | 0.56+0.2x | 0.55+0.1x | 0.54+0.1x |
| Asset Turnover | 0.140.0x | 0.140.0x | 0.150.0x | 0.140.0x | 0.140.0x | 0.130.0x | 0.150.0x | 0.130.0x |
| FCF Margin | 7.1%-4.4pp | 30.9%+1.1pp | 37.3%+4.5pp | 6.1%-0.4pp | 11.5%-2.7pp | 29.8%+0.3pp | 32.7%-2.2pp | 6.5%-6.1pp |
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Uipath Inc PATH | FY2026 | $1.6B | $282.3M | 17.5% | $7.3B | 57/100 |
| Varonis Sys Inc VRNS | FY2025 | $623.5M | -$129.3M | -20.7% | $5.3B | 54/100 |
| Sentinelone Inc S | FY2026 | $1.0B | -$450.7M | -45.0% | $6.9B | 45/100 |
| Wex Inc WEX | FY2025 | $2.7B | $304.1M | 11.4% | $6.6B | 55/100 |
| Informatica Inc INFA | FY2024 | $1.6B | $9.9M | 0.6% | $7.6B | 48/100 |
| Confluent, Inc. CFLT | FY2025 | $1.2B | -$295.3M | -25.3% | $11.1B | 51/100 |
Where Uipath Inc Ranks
Frequently Asked Questions
What is Uipath Inc's annual revenue?
Uipath Inc (PATH) reported $1.6B in total revenue for fiscal year 2026. This represents a 12.7% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Uipath Inc's revenue growing?
Uipath Inc (PATH) revenue grew by 12.7% year-over-year, from $1.4B to $1.6B in fiscal year 2026.
Is Uipath Inc profitable?
Yes, Uipath Inc (PATH) reported a net income of $282.3M in fiscal year 2026, with a net profit margin of 17.5%.
What is Uipath Inc's EBITDA?
Uipath Inc (PATH) had EBITDA of $73.7M in fiscal year 2026, measuring earnings before interest, taxes, depreciation, and amortization.
What is Uipath Inc's gross margin?
Uipath Inc (PATH) had a gross margin of 83.2% in fiscal year 2026, indicating the percentage of revenue retained after direct costs of goods sold.
What is Uipath Inc's operating margin?
Uipath Inc (PATH) had an operating margin of 3.5% in fiscal year 2026, reflecting the profitability of core business operations before interest and taxes.
What is Uipath Inc's net profit margin?
Uipath Inc (PATH) had a net profit margin of 17.5% in fiscal year 2026, representing the share of revenue converted into profit after all expenses.
What is Uipath Inc's return on equity (ROE)?
Uipath Inc (PATH) has a return on equity of 13.6% for fiscal year 2026, measuring how efficiently the company generates profit from shareholder equity.
What is Uipath Inc's free cash flow?
Uipath Inc (PATH) generated $352.2M in free cash flow during fiscal year 2026. This represents a 15.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Uipath Inc's operating cash flow?
Uipath Inc (PATH) generated $371.2M in operating cash flow during fiscal year 2026, representing cash generated from core business activities.
What are Uipath Inc's total assets?
Uipath Inc (PATH) had $3.2B in total assets as of fiscal year 2026, including both current and long-term assets.
What are Uipath Inc's capital expenditures?
Uipath Inc (PATH) invested $19.0M in capital expenditures during fiscal year 2026, funding long-term assets and infrastructure.
How much does Uipath Inc spend on research and development?
Uipath Inc (PATH) invested $385.2M in research and development during fiscal year 2026.
What is Uipath Inc's current ratio?
Uipath Inc (PATH) had a current ratio of 2.48 as of fiscal year 2026, which is generally considered healthy.
What is Uipath Inc's debt-to-equity ratio?
Uipath Inc (PATH) had a debt-to-equity ratio of 0.53 as of fiscal year 2026, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Uipath Inc's return on assets (ROA)?
Uipath Inc (PATH) had a return on assets of 8.9% for fiscal year 2026, measuring how efficiently the company uses its assets to generate profit.
What is Uipath Inc's P/E ratio?
Uipath Inc (PATH) trades at 20.1x earnings, its market capitalization divided by net income of $361.9M net income, trailing 12 months to July 31, 2026. The market capitalization is $7.3B as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Uipath Inc's price-to-sales ratio?
Uipath Inc (PATH) trades at 4.2x sales, its market capitalization divided by revenue of $1.7B revenue, trailing 12 months to July 31, 2026. The market capitalization is $7.3B as of Sep 9, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Uipath Inc's Altman Z-Score?
Uipath Inc (PATH) has an Altman Z-Score of 4.29, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Uipath Inc's Piotroski F-Score?
Uipath Inc (PATH) has a Piotroski F-Score of 6 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Uipath Inc's earnings high quality?
Uipath Inc (PATH) has an earnings quality ratio of 1.31x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Uipath Inc?
Uipath Inc (PATH) scores 57 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.